At first, let me introduce our platform, MONSTAR-SCREEN-2. MONSTAR-SCREEN-2 is a precision oncology platform in Japan, which targets more than 2,000 patients with advanced solid tumors. In MOSA Screen, as you know, the RNA fusion variant is a very important target in solid tumors. But unfortunately, the conventional DNA target panel sequencing often misses the important DNA fusion variant detection...
At first, let me introduce our platform, MONSTAR-SCREEN-2. MONSTAR-SCREEN-2 is a precision oncology platform in Japan, which targets more than 2,000 patients with advanced solid tumors. In MOSA Screen, as you know, the RNA fusion variant is a very important target in solid tumors. But unfortunately, the conventional DNA target panel sequencing often misses the important DNA fusion variant detection. And the RNA sequencing may detect more sensitively than the DNA panel sequence. And in MONSTAR-SCREEN-2, we perform the whole transcriptome sequencing in parallel to the whole exome sequencing. So in this analysis, we perform the clinical utility of the RNA sequencing for detection of the RNA fusions. In analysis, the approximately 5% of the patients harbor the fusion-by-fusion variants. And interestingly, the 60% of the fusion variants can’t be detected with DNA panel sequencing, can’t be detected with it by RNA sequencing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
